|
|
Article: Genzyme Transgenics Receives United States Patent for Transgenic Production of Antithrombin III in Goat's Milk.
- Article from:
- PR Newswire
- Article date:
- December 1, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Transgenically-Produced Anti-Clotting Therapeutic in Phase III Clinical Trials
FRAMINGHAM, Mass., Dec. 1 /PRNewswire/ -- Genzyme Transgenics Corporation (Nasdaq: GZTC) was today granted U.S. Patent 5,843,705, "Transgenically Produced Antithrombin III" by the United States Patent and Trademark Office. The patent covers recombinant human antithrombin III (rh AT III) produced in the milk of transgenic goats. Currently in phase III clinical trials in Europe and the United States, rh AT III is Genzyme Transgenics' lead product.
"This patent provides Genzyme Transgenics exclusive rights for the production of rh AT III in the milk of transgenic goats," said ...